A large number of variables are available for the assessment of disease activity in ankylosing spondylitis (AS). The aim of this study was to evaluate the validity of commonly used variables, to select a core set of valid variables for disease activity and finally to compute an AS disease activity score (AS-DAS). Data from two longitudinal studies were used. Principal component analysis and reliability analysis resulted in 1 1 factors: cervical mobility, lumbar flexion, subjective complaints, functional index (FI), enthesis index (El), inflammatory response, IgA, IgM, root joints, swollen joints and spinal mobility. Based on discriminating power, reproducibility and correlation with disease duration, seven single variables were selected. In a subsequent discriminant analysis, an AS-DAS was computed of five variables, i.e. subjective complaints, FI, HI, root joints and C-reactive protein, which should be validated in the future. A core set of process variables solves the problem of multiple testing in clinical trials, and improves comparability. 
selection of a core set of variables which are reliable, this reproducible and sensitive to change, might lead to the development of a disease activity score for AS.
PATIENTS AND METHODS

Patients
Records of AS patients participating in two prospective longitudinal studies were used. Patients of sex, aged between 18 and 60 yr, had to fulfil the modified New York criteria [18] . Patients participated either in a 48 week double-blind NSAID study (n 59), entering after a washout period for NSAIDs, or a 24 week open study with methotrexate (MTX), in which patients had to have failure of treatment with [19] . In both and asalazine studies, patients had to have active disease, defined as a clear need for anti-inflammatory, analgesic drug. In addition, they had to have at least two of the following features: ( I ) spinal pain, (2) morning stiffness of at least 30 min; (3) chest pain; (4) pain in both buttocks; (5) peripheral arthritis; (6) raised ESR ^ 30 mm/1st h or CRP > 20 mg/1 or IgA ^ 3.9 mg/1, participated first in the NSAID study and subsequently in the MTX study, only data from the MTX study of these patients were considered. Two other patients were retrospectively excluded from the NSAID study because they did not meet the above-described criteria for active disease. In total, there were 65 patients (48 men, 17 female); 62 of them were HLA-B27 positive, six had peripheral arthritis and four iridocyclitis. Mean age was 38 yr (s.D. = 9), mean disease duration 9 yr (S.D. Table I numbers o f features present _ for active disease are shown. Figure 2 shows the division of patients and the degree of pain and stiffness.
8). Features present at study entry are shown in
M easurements
For measurement o f disease activity, the following variables were assessed at every visit.
Clinical var
' 'S . Variables which have been measured on both sides, i.e. lumbar lateral flexion, cervical rotation and cervical lateral flexion, were reported as a good and bad score for each patient irrespective o f the side.
Occiput-to-wall
Definition o f disease activity and selection o f records
Patients were seen 12 times in the N SA ID study and eight times in the M TX study. This resulted in 736 records for these 65 patients. Patients' records were guided by the definitions o f high and low disease activity. Disease activity was defined as low in the N SAID study if patients had used a stable dose o f N SA ID s for at least 24 weeks, and in the MTX study if patients continued M TX after 24 weeks. Disease activity was defined as high at week 0 of both studies;
Median and percentiles 10 Table III ). Variables were scaled, and scaling factors were chosen to equalize the s .d . o f variables within each factor. Factor values then were calculated as the mean of the variables corresponding with the factor.
Discriminant 'S IS
Paired /-testing was performed on the factor values of the records of 36 patients with observations both with a high and low ase activity. For further analysis, Factor 1 was excluded because no significant change was found (P = 0.16). The number o f swollen joints also showed no significant change (P = 0.06); as this was possibly due to the small number o f patients with peripheral arthritis, we did not exclude this factor.
The stepwise forward discriminant analysis showed five significant steps entering: 'subjective complaints' (Factor 7), 'inflammatory response' (Factor 9), root joints (Factor 4), enthesis index (Factor 3) and IgA (Factor 10). Table IV shows the relative importance o f factors and variables used in the discriminant analysis. Canonical correlation was 0.64 and 80% were correctly classified.
The discriminating power, computed as the stan dardized differences from paired /-testing o f the 36 patients, and the correlations with the discriminant score ( 1 0 1 records) gave similar information about the factors used in the analyses (see Table IV ).
Disease duration
Variables and factor values from the N SA ID study o f weeks 0 and 1 2 and corresponding differences were used for the calculation of Spearman rank correlations with disease duration. Only statistically significant correlations are shown in Table V. In longitudinal studies, the quality of variables can be determined by the calculation of interperiod correlations. These intercorrelations can be plotted against time interval and a regression line can be calculated. In our study longitudinal data on AS patients were analysed to identify those variables which discriminate for disease activity. Since no 'gold standard' for disease activity in AS is available, pre-defined criteria for high and low disease activity were used. Two groups o f patients' records were formed: one group with high and one group with low disease activity. 
The intersection o f this line with the vertical axis (intercept) is an estimation of the direct measurement-remeasurement correlation (r(1) and this
